J2

HSP27 inhibitor J2 (J2) (J2) is a HSP27 inhibitor, inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function.

GSK-J2 is an inactive enantiomer of GSK-J1 that is lipophilic and serves as an inactive control for GSK-J21.

15-deoxy-Δ-12,14-Prostaglandin J2 is a PPARγ agonist.

Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

GSK-J2 sodium, the sodium form of GSK-J2, is an isomer of GSK-J1 and lacks specific activity. GSK-J1 is a potent inhibitor of H3K27me3 me2-demethylases JMJD3 KDM6B and UTX KDM6A [1].

J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.

SJ26 is a Wnt1 inhibitor known for its anticancer activity. It inhibits the expression of WNT1 and the downstream signaling pathways mediated by WNT1 in a G-quadruplex structure-dependent manner, thereby suppressing the migratory activity of cancer cells.

MJ210 is an orally active and blood-brain barrier-permeable modulator of the NF-κB and MAPK pathways, exhibiting neuroprotective properties. In vitro, 5 μM MJ210 can increase the survival rate of rotenone-treated SH-SY5Y cells to 81.9% and reduce levels of ROS. In vivo, 5 mg/kg MJ210 improves motor dysfunction in rat models of Parkinson's disease. MJ210 is useful for research in neurological disorders, including Parkinson's disease.

ErbB receptor family inhibitor

UAWJ248 is a SARS-CoV-2 Protease inhibitor. UAWJ248 provides new directions for the development of Mpro inhibitors as SARS-CoV-2 antivirals.

UAWJ246 is a SARS-CoV-2 Protease inhibitor (IC50 = 45 nM). UAWJ246 provides new directions for the development of Mpro inhibitors as SARS-CoV-2 antivirals.

AJ2-30 is an SLCl5A4 inhibitor that inhibits TLR9-mediated B cell activation and inhibits MDP transporter.AJ2-30 inhibits endogenous NOD signaling in human and mouse macrophages.AJ2-30 can be used for the study of inflammation.

J27644 is a potent HDAC (histone deacetylase) inhibitor that mitigates TGF-β (transforming growth factor beta)-induced pulmonary fibrosis [1].

δ-Buthitoxin-Hj2a, a potent scorpion-venom peptide, acts as a NaV1.1 agonist with an EC50 value of 32 nM and is employed in Dravet syndrome (DS) research [1].

XSJ2-46, a 5'-amino NI analog, is an antiviral agent possessing anti-Zika virus properties and demonstrates reasonable inhibition of RNA-dependent RNA polymerases (RdRp), with an IC50 of 8.78 μM [1].

AJ2-71 is a SLC15A4 inhibitor that suppresses IFN-α production and obstructs SLC15A4-mediated MDP transport, making it suitable for research of inflammation [1].

J208 is a dual inhibitor of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) that hinders cancer cell proliferation and the migration invasion of triple-negative breast cancer (TNBC) cells. It induces apoptosis and causes cell cycle arrest at the G0 G1 phase. Additionally, J208 activates the innate immune signaling pathway in TNBC by inducing the expression of endogenous retroviruses (ERVs) [1].

Microcin J25 (MccJ25) is a cyclopeptide antibiotic made up of 21 unmodified amino acid residues. It effectively inhibits the DNA-dependent RNA polymerase (RNAP) of Gram-negative bacteria and exhibits antibacterial activity.

THJ2201 N-pentanoic acid metabolite belongs to synthetic cannabinoid metabolites. It is a metabolite of THJ2201.

Deoxynivalenol (Vomitoxin) is a mycotoxin produced by Fusarium spp. of the single trichothecene family and is commonly found in contaminated food and feed.Deoxynivalenol crosses the intestinal mucosa via a cellular bypass at the tight junctions.Deoxynivalenol transporters are unaffected by inhibitors of P-glycoprotein (PgP) or multidrug resistance-associated protein (MRP). Deoxynivalenol commonly causes diarrhea, vomiting, and gastrointestinal inflammation in humans and animals.

Fervenulin is isolated from a nematicidal actinomycete Streptomyces sp. CMU-MH021 with nematicidal activity. It also inhibits egg hatch and J2 mortality of M. incognita (MICs: 30 μg mL and 120 μg mL, respectively).

GSK J5 HCl is the hydrochloride form of GSK J5. GSK J5 is an inactive isomer of GSK J4 and a cell-permeable ester derivative of inactive control GSK J2.

CAY10410 is an analog of prostaglandin D2/prostaglandin J2 (PGD2/PGJ2) with structural modifications intended to give it PPARγ ligand activity and resistance to metabolism. 15-deoxy-δ12,14-PGJ2 has been shown to be a potent ligand for PPARγ. Metabolism of the cyclopentenone prostaglandins PGA2, PGJ2, and δ12-PGJ2 occurs via glutathione addition across the α,β unsaturated enone. CAY10410 was designed as an analog of the PPARγ-binding prostaglandins which could not undergo this conjugation reaction. In human neuroblastoma SH-SY5Y cells, CAY10410 was not cytotoxic at up to 25 μM. It also failed to covalently modify thioredoxin or induce oxidative stress at 50 μM.

Oxmetidine mesylate is an antagonist to Histamine H2 Receptors